Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer

Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ping, Zhang, Xu, Ding, Renbo, Yang, Linglin, Lyu, Xueying, Zeng, Jianming, Lei, Josh Haipeng, Wang, Lijian, Bi, Jiong, Shao, Nan, Shu, Ditian, Wu, Bin, Wu, Jingbo, Yang, Zhihui, Wang, Haiyan, Wang, Biqiong, Xiong, Kang, Lu, Yun, Fu, Shaozhi, Choi, Tak Kan, Lon, Ng Wai, Zhang, Aiping, Tang, Dongyang, Quan, Yingyao, Meng, Ya, Miao, Kai, Sun, Heng, Zhao, Ming, Bao, Jiaolin, Zhang, Lei, Xu, Xiaoling, Shi, Yanxia, Lin, Ying, Deng, Chuxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596108/
https://www.ncbi.nlm.nih.gov/pubmed/34605222
http://dx.doi.org/10.1002/advs.202101176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596108/
https://www.ncbi.nlm.nih.gov/pubmed/34605222
http://dx.doi.org/10.1002/advs.202101176

Ejemplares similares